Background: Obesity substantially increases the risk of the development of chronic kidney disease. Adipose tissue expresses all of the components of the renin-angiotensin system (RAS), contributing to the high prevalence of hypertension in obese patients and driving renal hyperfiltration and subsequent glomerular injury. Methods: We performed a retrospective cohort study using a United Kingdom primary care database, evaluating the effect of time-updated exposure to RAS blockade versus all other antihypertensive medications in obese, hypertensive, non-diabetic patients. We used Cox proportional hazards modeling with and without marginal structural modeling to assess the hazards of developing a primary outcome of 50% reduction in estimated glomerular filtration rate (eGFR) (across 2 consecutive values), end stage renal disease or death. Results: A total of 219,701 patients met inclusion criteria, with a median 7.2 years of follow-up. Median baseline eGFR was 72.6 ml/min/1.73 m2. Compared to other antihypertensive medications, patients treated with RAS blockade had a modestly elevated hazard of adverse renal outcomes using traditional Cox regression (hazard ratio (HR) 1.04, 95% CI 1.01-1.07) and no significantly increased hazard by marginal structural modeling (HR 1.02, 95% CI 0.97-1.08). Patients treated with RAS blockade had a significantly reduced hazard of incident diabetes, but no significant difference in mortality. Conclusion: This study, conducted in a large real-world cohort, provides evidence that RAS blockade may not provide benefit with regard to longitudinal renal outcomes in obese, hypertensive patients. Further research is needed to elucidate the hemodynamic and renoprotective role of antihypertensive medications in obese patients.

Keywords:
Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker, Renin-angiotensin system blockade, Obesity, Hypertension, Chronic kidney disease
1.
Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-1727.
2.
Ogden CL, Carroll MD, Kit BK, Flegal KM: Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014;311:806-814.
3.
Boniface S, Bridges S, Craig R, Darton R, Fuller E, Hancock R, Henderson C, Knott C, Mandalia D, Mindell J, Moody A, Morciano M, Ng Fat L, Oyebode O, Robinson C, Sadler K, Sutton R, Wittenberg R: Health Survey for England 2013: Adult Anthropometric Measures, Overweight and Obesity. Health and Social Care Information Centre, Leeds: Department of Epidemiology and Public Health, University College London, 2014.
4.
Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M: Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011;378:815-825.
5.
Bonnet F, Deprele C, Sassolas A, Moulin P, Alamartine E, Berthezène F, Berthoux F: Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001;37:720-727.
6.
Berthoux F, Mariat C, Maillard N: Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy. Nephrol Dial Transplant 2013;28(suppl 4):iv160-iv166.
7.
Manson JE, Skerrett PJ, Greenland P, VanItallie TB: The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. Arch Intern Med 2004;164:249-258.
8.
Iseki K, Ikemiya Y, Fukiyama K: Predictors of end-stage renal disease and body mass index in a screened cohort. Kidney Int Suppl 1997;63:S169-S170.
9.
Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S: Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004;65:1870-1876.
10.
Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS: Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21-28.
11.
Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J: The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004;140:167-174.
12.
Lea J, Cheek D, Thornley-Brown D, Appel L, Agodoa L, Contreras G, Gassman J, Lash J, Miller ER 3rd, Randall O, Wang X, McClellan W; AASK Study Investigators: Metabolic syndrome, proteinuria, and the risk of progressive CKD in hypertensive African Americans. Am J Kidney Dis 2008;51:732-740.
13.
Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD: Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011;6:2364-2373.
14.
Townsend RR, Anderson AH, Chen J, Gadebegku CA, Feldman HI, Fink JC, Go AS, Joffe M, Nessel LA, Ojo A, Rader DJ, Reilly MP, Teal V, Teff K, Wright JT, Xie D: Metabolic syndrome, components, and cardiovascular disease prevalence in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Nephrol 2011;33(6):477-484.
15.
Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047.
16.
Praga M, Hernandez E, Morales E, Campos AP, Valero MA, Martinez MA, Leon M: Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001;16:1790-1798.
17.
Amann K, Benz K: Structural renal changes in obesity and diabetes. Semin Nephrol 2013;33:23-33.
18.
Saxena AB, Myers BD, Derby G, Blouch KL, Yan J, Ho B, Tan JC: Adaptive hyperfiltration in the aging kidney after contralateral nephrectomy. Am J Physiol Renal Physiol 2006;291:F629-F634.
19.
Zhuo JL, Li XC: New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II. Peptides 2011;32:1551-1565.
20.
Cassis LA, Police SB, Yiannikouris F, Thatcher SE: Local adipose tissue renin-angiotensin system. Curr Hypertens Rep 2008;10:93-98.
21.
Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE: Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001;12:1211-1217.
22.
Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U: Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000;278:F817-F822.
23.
Hall JE, Brands MW, Dixon WN, Smith MJ Jr: Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension 1993;22:292-299.
24.
Ribstein J, du Cailar G, Mimran A: Combined renal effects of overweight and hypertension. Hypertension 1995;26:610-615.
25.
Thethi T, Kamiyama M, Kobori H: The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep 2012;14:160-169.
26.
Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y: The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003;14:1480-1486.
27.
Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005;45:356-362.
28.
Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE: Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000;35:695-707.
29.
Chiurchiu C, Remuzzi G, Ruggenenti P: Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J Am Soc Nephrol 2005;16(suppl 1):S58-S63.
30.
Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48.
31.
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-1863.
32.
Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995;155:1073-1080.
33.
Ahmed SB, Fisher ND, Stevanovic R, Hollenberg NK: Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension 2005;46:1316-1320.
34.
THIN Data Statistics 2014. http://csdmruk.cegedim.com/ (December 1, 2014).
35.
Lewis JD, Bilker WB, Weinstein RB, Strom BL: The relationship between time since registration and measured incidence rates in the general practice research database. Pharmacoepidemiol Drug Saf 2005;14:443-451.
36.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; Ckd-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
37.
Office for National Statistics: Census, Key Statistics and Quick Statistics for Local Authorities in the United Kingdom - Part 1 2011. http://www.ons.gov.uk/ons/index.html (cited November 1, 2013).
38.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
39.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
40.
Townsend P: Poverty in the United Kingdom. London, Allen Lane and Penguin Books, 1979.
41.
Chirinos JA, Franklin SS, Townsend RR, Raij L: Body mass index and hypertension hemodynamic subtypes in the adult US population. Arch Intern Med 2009;169:580-586.
42.
De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, Nappi F, Conte G, Minutolo R: Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 2013;61:2461-2467.
43.
De Nicola L, Borrelli S, Gabbai FB, Chiodini P, Zamboli P, Iodice C, Vitiello S, Conte G, Minutolo R: Burden of resistant hypertension in hypertensive patients with non-dialysis chronic kidney disease. Kidney Blood Press Res 2011;34:58-67.
44.
Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi T, Shimomura I: Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009;84:164-172.
45.
Hirata A, Maeda N, Nakatsuji H, Hiuge-Shimizu A, Okada T, Funahashi T, Shimomura I: Contribution of glucocorticoid-mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction. Biochem Biophys Res Commun 2012;419:182-187.
46.
Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, Fox CS, Meigs JB, Levy D, Larson MG, Selhub J, D'Agostino RB Sr, Wang TJ, Vasan RS: Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham offspring study. Circulation 2007;116:984-992.
47.
de Paula RB, da Silva AA, Hall JE: Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004;43:41-47.
48.
Anderson AH, Yang W, Townsend RR, Pan Q, Chertow GM, Kusek JW, Charleston J, He J, Kallem R, Lash JP, Miller ER 3rd, Rahman M, Steigerwalt S, Weir M, Wright JT Jr, Feldman HI; Chronic Renal Insufficiency Cohort Study Investigators: Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study. Ann Intern Med 2015;162:258-265.
49.
Kovesdy CP, Lu JL, Molnar MZ, Ma JZ, Canada RB, Streja E, Kalantar-Zadeh K, Bleyer AJ: Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. JAMA Intern Med 2014;174:1442-1449.
50.
Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU: The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int 2011;80:17-28.
51.
Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-917.
52.
Andraws R, Brown DL: Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007;99:1006-1012.
53.
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-481.
54.
Joffe MM, Ten Have TR, Feldman HI, Kimmel SE: Model selection, confounder control, and marginal structural models: review and new applications. Am Stat 2004;58:272-279.
55.
Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560.
56.
Cole SR, Hernán MA: Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008;168:656-664.
57.
Gilg J, Pruthi R, Fogarty D: UK renal registry 17th annual report: chapter 1 UK renal replacement therapy incidence in 2013: national and centre-specific analyses. Nephron 2015;129(suppl 1):1-29.
58.
Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-2431.
59.
Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-693.
60.
Jun M, Turin TC, Woodward M, Perkovic V, Lambers Heerspink HJ, Manns BJ, Tonelli M, Hemmelgarn BR: Assessing the validity of surrogate outcomes for ESRD: a meta-analysis. J Am Soc Nephrol 2015;26:2289-2302.
61.
Mallamaci F, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Remuzzi G, Zoccali C; REIN Study Group: ACE inhibition is renoprotective among obese patients with proteinuria. J Am Soc Nephrol 2011;22:1122-1128.
62.
Alicic R, Tuttle KR: Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy? Curr Hypertens Rep 2007;9:393-402.
63.
Delanaye P, Mariat C: The applicability of eGFR equations to different populations. Nat Rev Nephrol 2013;9:513-522.
64.
Delanaye P, Krzesinski JM: Indexing of renal function parameters by body surface area: intelligence or folly? Nephron Clin Pract 2011;119:c289-c292.
65.
Eriksen BO, Melsom T, Mathisen UD, Jenssen TG, Solbu MD, Toft I: GFR normalized to total body water allows comparisons across genders and body sizes. J Am Soc Nephrol 2011;22:1517-1525.
66.
Bouquegneau A, Vidal-Petiot E, Vrtovsnik F, Cavalier E, Rorive M, Krzesinski JM, Delanaye P, Flamant M: Modification of diet in renal disease versus chronic kidney disease epidemiology collaboration equation to estimate glomerular filtration rate in obese patients. Nephrol Dial Transplant 2013;28(suppl 4):iv122-iv130.
67.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter Suppl 2013;3:1-150.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.